Skip to content

Secondary prevention after stroke and TIA

TL;DR — Secondary prevention is mechanism-dependent, not a single drug bundle: establish whether the event was non-cardioembolic, cardioembolic, large-artery atherosclerotic, small-vessel, or hemorrhagic before choosing antithrombotic and procedural strategies (Kleindorfer 2021, PMID 34024117). Blood-pressure lowering after stroke reduced recurrent stroke from 14% to 10% over four years in PROGRESS, and intensive lipid lowering reduced major cardiovascular events in patients with atherosclerotic stroke or TIA (PROGRESS Collaborative Group 2001, PMID 11589932; Amarenco 2020, PMID 31738483). For minor non-cardioembolic stroke or high-risk TIA, aspirin plus clopidogrel started within 12–24 hours reduces early ischemic events, but benefit is front-loaded and prolonged dual therapy adds hemorrhage without durable benefit (Wang 2013, PMID 23803136; Johnston 2018, PMID 29766750; Diener 2004, PMID 15276392). Symptomatic severe carotid stenosis benefits from timely endarterectomy, whereas intracranial stenting and EC–IC bypass have failed to beat aggressive medical treatment in randomized trials (Barnett 1991, PMID 1852179; Chimowitz 2011, PMID 21899409; Powers 2011, PMID 22068990).

Start with cause, timing, and competing hazards

Prevention begins during the index admission because recurrent ischemic risk is concentrated in the first days after TIA or minor stroke, while hemorrhagic transformation, infarct size, dysphagia, falls, renal function, and planned procedures alter the safety of treatment (Kleindorfer 2021, PMID 34024117).

Mechanism or context Prevention backbone What should not be generalized
Non-cardioembolic ischemic stroke/TIA Antiplatelet therapy, blood-pressure control, lipid lowering, lifestyle Routine anticoagulation is not a substitute for antiplatelet therapy (Kleindorfer 2021, PMID 34024117)
Atrial fibrillation/cardioembolism Oral anticoagulation after individualized timing Dual antiplatelet therapy is not equivalent to anticoagulation; see cardioembolic and cryptogenic stroke
Symptomatic extracranial carotid stenosis Medical therapy plus timely revascularization when benefit exceeds peri-procedural risk Trial benefit depends on stenosis, timing, sex, age, disability, and operative risk (Barnett 1991, PMID 1852179; ECST 1998, PMID 9593407)
Symptomatic intracranial atherosclerosis Intensive medical therapy and short-course dual antiplatelet therapy in selected severe disease Wingspan stenting had excess early stroke/death (Chimowitz 2011, PMID 21899409)
Lacunar stroke Blood-pressure control plus a single antiplatelet Long-term aspirin–clopidogrel did not reduce recurrence and nearly doubled major hemorrhage (SPS3 2012, PMID 22931315)
Prior intracerebral hemorrhage Treat blood pressure; weigh ischemic indication against hemorrhage phenotype RESTART is reassuring but not proof of safety in every lobar/microbleed phenotype (RESTART Collaboration 2019, PMID 31128924)

Blood pressure: the highest-yield modifiable exposure

PROGRESS randomized 6,105 people with prior stroke or TIA, including participants without baseline hypertension. A perindopril-based regimen lowered blood pressure by 9/4 mm Hg and reduced recurrent stroke from 14% to 10% over four years: relative risk reduction 28% (95% CI 17–38), absolute risk reduction 4%, approximate NNT 25 (PROGRESS Collaborative Group 2001, PMID 11589932).

In SPS3, 3,020 patients with MRI-defined lacunar stroke were assigned systolic targets of 130–149 or <130 mm Hg. Achieved systolic pressure at one year was 138 versus 127 mm Hg; the lower target produced a non-significant reduction in all stroke but a significant reduction in intracerebral hemorrhage, supporting feasibility while leaving the exact ischemic-stroke target less certain (SPS3 Study Group 2013, PMID 23726159).

Trial Population Contrast Main quantitative result Interpretation
PROGRESS 6,105 prior stroke/TIA Perindopril-based regimen vs placebo Stroke 10% vs 14%; RRR 28% (95% CI 17–38) over 4 y Benefit extends beyond people labeled hypertensive (PMID 11589932)
SPS3 BP arm 3,020 recent lacunar strokes SBP <130 vs 130–149 mm Hg Achieved 127 vs 138 mm Hg; all-stroke reduction did not reach significance Supports a lower target, particularly for hemorrhage prevention (PMID 23726159)

The practical target is usually <130/80 mm Hg for most patients, but trial entry populations, orthostatic symptoms, severe bilateral stenosis, frailty, and early post-stroke hemodynamics matter; a target is a longitudinal strategy, not an instruction for abrupt lowering during unstable acute ischemia (Kleindorfer 2021, PMID 34024117).

Lipids and atherosclerotic risk

SPARCL randomized 4,731 patients with recent stroke/TIA, LDL 100–190 mg/dL, and no known coronary disease to atorvastatin 80 mg or placebo. Mean on-treatment LDL was 73 versus 129 mg/dL; fatal or nonfatal stroke occurred in 11.2% versus 13.1% over median 4.9 years (adjusted HR 0.84, 95% CI 0.71–0.99; absolute five-year reduction 2.2%) (Amarenco 2006, PMID 16899775).

Treat Stroke to Target randomized 2,860 patients with recent ischemic stroke/TIA and documented atherosclerosis to LDL <70 versus 90–110 mg/dL. The lower target reduced the composite of ischemic stroke, myocardial infarction, urgent coronary/carotid revascularization, or cardiovascular death, establishing a target strategy rather than merely a statin-versus-placebo effect (Amarenco 2020, PMID 31738483).

The LDL evidence is strongest for atherosclerotic disease. Treatment intensity should account for baseline LDL, statin tolerance, drug interactions, diabetes risk, hemorrhage phenotype, and whether ezetimibe or another non-statin agent is needed to reach the target (Kleindorfer 2021, PMID 34024117).

Antiplatelet therapy

Long-term single-agent choices

Acceptable long-term options for non-cardioembolic stroke include aspirin, clopidogrel, and aspirin plus extended-release dipyridamole (Kleindorfer 2021, PMID 34024117).

CAPRIE randomized 19,185 people with recent ischemic stroke, myocardial infarction, or peripheral arterial disease. Clopidogrel reduced the composite of ischemic stroke, myocardial infarction, or vascular death by 8.7% relative to aspirin across the pooled vascular population; the modest aggregate advantage does not mean a large stroke-specific advantage (CAPRIE Steering Committee 1996, PMID 8918275).

ESPS-2 randomized 6,602 people after stroke/TIA: versus placebo, stroke risk fell 18% with aspirin, 16% with modified-release dipyridamole, and 37% with the combination over two years, although headache and tolerability shape real-world selection (Diener 1996, PMID 8981292).

Short-term dual antiplatelet therapy

Trial Entry window/population Regimen Efficacy Bleeding signal
CHANCE ≤24 h; 5,170 Chinese patients with minor stroke/high-risk TIA Clopidogrel 90 d + aspirin 21 d vs aspirin 90-d stroke 8.2% vs 11.7%; HR 0.68 (95% CI 0.57–0.81) No increase in moderate/severe hemorrhage (Wang 2013, PMID 23803136)
POINT ≤12 h; 4,881 international patients Clopidogrel + aspirin for 90 d vs aspirin Major ischemic events 5.0% vs 6.5%; HR 0.75 (95% CI 0.59–0.95) Major hemorrhage 0.9% vs 0.4%; HR 2.32 (95% CI 1.10–4.87) (Johnston 2018, PMID 29766750)
THALES ≤24 h; NIHSS ≤5 or high-risk TIA Ticagrelor + aspirin for 30 d vs aspirin Stroke/death 5.5% vs 6.6%; HR 0.83 (95% CI 0.71–0.96) Severe bleeding 0.5% vs 0.1% (Johnston 2020, PMID 32668111)

The synthesis is duration-sensitive: early platelet inhibition prevents early recurrence, while bleeding continues to accumulate. Short-course aspirin–clopidogrel is therefore for a defined early high-risk phenotype, not routine indefinite therapy (Kleindorfer 2021, PMID 34024117).

Why long-term dual therapy usually fails

MATCH enrolled 7,599 high-risk patients already receiving clopidogrel. Adding aspirin changed the primary vascular composite from 16.7% to 15.7%, an absolute 1.0-point difference that was not significant, while life-threatening bleeding rose from 1.3% to 2.6% (Diener 2004, PMID 15276392).

SPS3 enrolled 3,020 patients with MRI-proven lacunar infarcts. Aspirin–clopidogrel did not reduce recurrent stroke versus aspirin (2.5% vs 2.7% per year; HR 0.92, 95% CI 0.72–1.16), nearly doubled major hemorrhage, and increased mortality (SPS3 Investigators 2012, PMID 22931315).

Symptomatic extracranial carotid stenosis

NASCET established large benefit for endarterectomy in recently symptomatic 70–99% stenosis when performed with acceptable peri-operative risk: the two-year ipsilateral-stroke risk was 9% with surgery versus 26% with medical care in the original high-grade cohort (Barnett 1991, PMID 1852179).

ECST similarly found that untreated ipsilateral major-stroke risk rose sharply with severe stenosis, while surgery carried an approximately 7% major stroke/death hazard; benefit therefore depends on baseline stroke risk and procedural safety (ECST Collaborative Group 1998, PMID 9593407).

CREST randomized 2,502 symptomatic or asymptomatic patients to carotid stenting or endarterectomy. The four-year composite did not differ (7.2% vs 6.8%; HR 1.11, 95% CI 0.81–1.51), but the components moved oppositely: peri-procedural stroke was more frequent with stenting and myocardial infarction more frequent with endarterectomy (Brott 2010, PMID 20505173).

Decision variable Why it changes net benefit
Degree measured by a validated method NASCET and ECST used different denominator conventions; percentages are not interchangeable without recalculation (PMID 1852179; PMID 9593407)
Time since symptoms Preventable recurrence is front-loaded; delayed surgery loses absolute benefit (Kleindorfer 2021, PMID 34024117)
Age and anatomy Older age and difficult arch anatomy tend to increase stenting hazard; local operator outcomes matter (Brott 2010, PMID 20505173)
Baseline disability and life expectancy Revascularization prevents future events; benefit is attenuated when procedural harm or competing mortality dominates

Intracranial atherosclerosis and arterial occlusion

WASID compared warfarin with aspirin in 569 patients with symptomatic 50–99% intracranial stenosis. Enrollment stopped for safety: death was 9.7% with warfarin versus 4.3% with aspirin and major hemorrhage 8.3% versus 3.2%, without an efficacy advantage sufficient to offset harm (Chimowitz 2005, PMID 15800226).

SAMMPRIS randomized recent symptomatic 70–99% intracranial stenosis to aggressive medical management with or without Wingspan stenting. Thirty-day stroke/death was 14.7% with stenting versus 5.8% with medical therapy; longer follow-up did not reveal a late advantage that recovered the peri-procedural deficit (Chimowitz 2011, PMID 21899409; Derdeyn 2014, PMID 24168957).

COSS selected 195 symptomatic carotid-occlusion patients with PET evidence of increased oxygen extraction fraction. EC–IC bypass did not reduce two-year ipsilateral stroke because a 14.4% peri-operative stroke rate offset subsequent hemodynamic benefit (Powers 2011, PMID 22068990).

These trials do not prove that every carefully selected rescue procedure is futile; they do establish aggressive medical management as the comparator and make procedural risk inseparable from any claim of efficacy.

Insulin resistance, diabetes, and lifestyle

IRIS randomized 3,876 insulin-resistant patients without diabetes after stroke/TIA. Pioglitazone reduced stroke or myocardial infarction from 11.8% to 9.0% over 4.8 years (HR 0.76, 95% CI 0.62–0.93) and incident diabetes from 7.7% to 3.8%, but increased weight gain, edema, and fracture, making net benefit phenotype-dependent (Kernan 2016, PMID 26886418).

Diet, physical activity, tobacco cessation, sleep, weight, and medication adherence affect several causal pathways simultaneously. The strongest randomized diet evidence is cardiovascular rather than stroke-recurrence-specific: PREDIMED reduced a composite of myocardial infarction, stroke, or cardiovascular death in high-risk adults without established cardiovascular disease, so extrapolation to post-stroke care should be labeled as such (Estruch 2013, PMID 23432189).

The AHA scientific statement emphasizes repeated behavioral counseling, goal setting, self-monitoring, and follow-up rather than one-time advice; post-stroke aphasia, cognitive impairment, fatigue, transport, food access, and caregiver capacity determine whether the intervention is deliverable (Artinian 2010, PMID 20625115).

After intracerebral hemorrhage

RESTART randomized 537 survivors of antithrombotic-associated intracerebral hemorrhage to start or avoid antiplatelet therapy. Recurrent ICH occurred in 4% versus 9% during initial follow-up (adjusted HR 0.51, 95% CI 0.25–1.03); the result did not show the excess hemorrhage clinicians feared, but its confidence interval and selected survivor population preclude a blanket safety claim (RESTART Collaboration 2019, PMID 31128924).

Extended follow-up to median three years found recurrent ICH in 8.2% assigned antiplatelets versus 9.3% avoiding them (adjusted HR 0.87, 95% CI 0.49–1.55), with major vascular events in 26.8% versus 32.5% (HR 0.79, 95% CI 0.58–1.08) (Al-Shahi Salman 2021, PMID 34477823).

The evidence supports individualized resumption when the occlusive-vascular indication is strong; it does not determine the ideal timing or fully resolve risk in probable cerebral amyloid angiopathy, extensive lobar microbleeds, or superficial siderosis.

Implementation failures are treatment failures

Secondary-prevention trials generally test assigned strategies under repeated follow-up. In practice, etiologic uncertainty, cost, adverse effects, fragmented transitions, under-treatment of hypertension and lipids, and non-persistence erode the achievable effect (Kleindorfer 2021, PMID 34024117).

Follow-up checkpoint Minimum research-grade question
Before discharge Is the mechanism sufficiently established to justify the antithrombotic choice?
1–4 weeks Are early dual therapy and anticoagulation transitions scheduled to stop/start on the intended date?
4–12 weeks Are home BP and LDL trajectories at target, and are adverse effects being measured?
3–12 months Has new AF, recurrent TIA/stroke, bleeding, cognitive decline, or non-persistence changed the mechanism–risk balance?

Open questions

  • What is the optimal systolic target after non-lacunar ischemic stroke in patients with severe stenosis or impaired autoregulation? PROGRESS proves benefit from lowering, while SPS3 directly compared targets only in lacunar stroke (PMID 11589932; PMID 23726159).
  • Can genotype- or platelet-function-guided antiplatelet selection improve outcomes beyond short-course empirical dual therapy without creating treatment delay (Wang 2013, PMID 23803136; Johnston 2018, PMID 29766750)?
  • Which contemporary patients with symptomatic intracranial stenosis have recurrence despite genuinely achieved SAMMPRIS-level risk-factor control, and can any procedure improve outcomes in that residual-risk subgroup (Derdeyn 2014, PMID 24168957)?
  • How should antiplatelet resumption after ICH be stratified by amyloid angiopathy markers and competing coronary risk? RESTART was reassuring but imprecise in imaging-defined subgroups (Al-Shahi Salman 2021, PMID 34477823).
  • Which delivery models close the gap between trial-level risk-factor control and routine care for people with aphasia, cognitive impairment, or socioeconomic barriers (Artinian 2010, PMID 20625115)?

References

  1. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2021;52:e364-e467. PMID 34024117
  2. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041. PMID 11589932
  3. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559. PMID 16899775
  4. Amarenco P, Kim JS, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382:9-19. PMID 31738483
  5. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11-19. PMID 23803136
  6. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379:215-225. PMID 29766750
  7. Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383:207-217. PMID 32668111
  8. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH). Lancet. 2004;364:331-337. PMID 15276392
  9. SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817-825. PMID 22931315
  10. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996;348:1329-1339. PMID 8918275
  11. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in secondary prevention of stroke. J Neurol Sci. 1996;143:1-13. PMID 8981292
  12. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365:993-1003. PMID 21899409
  13. Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis: SAMMPRIS final results. Lancet. 2014;383:333-341. PMID 24168957
  14. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305-1316. PMID 15800226
  15. Powers WJ, Clarke WR, Grubb RL Jr, et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia. JAMA. 2011;306:1983-1992. PMID 22068990
  16. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445-453. PMID 1852179
  17. European Carotid Surgery Trialists' Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results. Lancet. 1998;351:1379-1387. PMID 9593407
  18. Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363:11-23. PMID 20505173
  19. SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-515. PMID 23726159
  20. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321-1331. PMID 26886418
  21. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-1290. PMID 23432189
  22. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults. Circulation. 2010;122:406-441. PMID 20625115
  23. RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART). Lancet. 2019;393:2613-2623. PMID 31128924
  24. Al-Shahi Salman R, Dennis MS, Sandercock PAG, et al. Effects of antiplatelet therapy after stroke caused by intracerebral hemorrhage: extended follow-up of RESTART. JAMA Neurol. 2021;78:1179-1186. PMID 34477823